COVID-19: benefits and risks of passive immunotherapeutics

Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respira...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ankur, Karki, Rashmi, Dandu, Himanshu R, Dhama, Kuldeep, Bhatt, Madan LB, Saxena, Shailendra K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Mini-Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544960/
https://www.ncbi.nlm.nih.gov/pubmed/32962524
http://dx.doi.org/10.1080/21645515.2020.1808410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544960/
https://www.ncbi.nlm.nih.gov/pubmed/32962524
http://dx.doi.org/10.1080/21645515.2020.1808410

Ejemplares similares